Vertex制药公司击败了2025年Q2收入估计,并重申了全年指导。 Vertex Pharmaceuticals beat Q2 2025 earnings estimates and reaffirmed full-year guidance.

Vertex制药公司报告,2025年Q2成果强劲,经调整的EPS为4.52美元,粗略估算为2.8美元,收入为29.4亿美元,比年增长11.3%。 Vertex Pharmaceuticals reported strong Q2 2025 results, with adjusted EPS of $4.52, beating estimates by $0.28, and revenue of $2.94 billion, up 11.3% year-over-year. 该公司重申其2025年全年收入指导,在EPS中预测为15.63美元。 The company reaffirmed its full-year 2025 earnings guidance, projecting $15.63 in EPS. 机构所有权仍然高居90.96%,UBS资产管理公司增加了股份,LRI投资有限公司减少了股份。 Institutional ownership remains high at 90.96%, with UBS Asset Management increasing its stake and LRI Investments LLC reducing holdings. 分析师对库存的评级是“机动购买”,目标为494.38美元。 Analysts rate the stock a "Moderate Buy" with a $494.38 target. 该库存关闭407.79美元,接近50天移动平均数393.91美元。 The stock closed at $407.79, near its 50-day moving average of $393.91.